<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04306211</url>
  </required_header>
  <id_info>
    <org_study_id>1810997768</org_study_id>
    <nct_id>NCT04306211</nct_id>
  </id_info>
  <brief_title>Comparison of Oxygenation Between Nasal PAP vs Nasal During Propofol-based Sedation for EUS</brief_title>
  <acronym>SuperNo2VA</acronym>
  <official_title>Comparison of Oxygenation Between Nasal Positive Airway Pressure (PAP) Versus Standard Care During Propofol-based Sedation for Endoscopic Ultrasound in an Ambulatory Surgical Setting: a Prospective Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vyaire Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized controlled single site study involves oxygenation, continuous positive airway
      pressure, and ventilation of subject via nasal mask and oxygenationvia closed facemask. The
      intervention of the study are delivery form of supplemental oxygen, bag-mask ventilation, and
      continuous nasal CPAP intraoperatively and in the post anesthesia care period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      124 patients with BMI&gt; or equal to 35kg.m2 or documented Obstructive Sleep Apnea scheduled
      for an EUS with Propofol sedation will be randomized to CPAP vs nasal mask for oxygenation
      during their procedure. Patients will be monitored every 2 minutes during the procedure and
      in the recovery area until discharge. If patients have difficulty or refuse to wear the mask,
      2 or more simultaneous or non-synchronous adverse events, change in heart rhythm or ST
      changes on EKG they will immediately changed to the other group. The ansethesiologist,
      gastroenterologist &amp; patient will complete post-procedure questionnaires regarding their
      opinion of the oxygen delivery system.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 20, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2029</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2029</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Random assignment to oxygen delivery system: facial mask or SuperNO2VA Et. Crossover to other oxygen delivery system if patient experiences difficulty with assigned system.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Random assignment to oxygen delivery system: facial mask or SuperNO2VA Et. Crossover to other oxygen delivery system if patient experiences difficulty with assigned system.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Benefit of nasal PAP versus nasal administration of oxygen</measure>
    <time_frame>oxygen saturation below 90% for &gt;15 seconds during procedure</time_frame>
    <description>Compare the incidence, duration, and severity of oxygen desaturation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total amount of Propofol for adequate sedation</measure>
    <time_frame>Total duration of procedure</time_frame>
    <description>Compares amounts of Propofol for induction and entire procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified observer's Assessment and Alertness/Sedation Scale (MOAAS)</measure>
    <time_frame>baseline, during procedure,and immediate post procedure in recovery area</time_frame>
    <description>Compare MOAAS immediately prior to intubation and during procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural interruptions</measure>
    <time_frame>Baseline &amp; duration of procedure</time_frame>
    <description>Compare incidence, duration and reason for procedural interruptions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Endoscopic Ultrasound</condition>
  <arm_group>
    <arm_group_label>Facial mask</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>facial mask for oxygen delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SuperNO2VA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SuperNO2VA is CPAP device to deliver oxygen with nasal mask rather than with facial mask</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SuperNO2VA</intervention_name>
    <description>SUPERNO2VA is nasal PAP device for oxygen delivery</description>
    <arm_group_label>Facial mask</arm_group_label>
    <arm_group_label>SuperNO2VA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years of age or older

          2. Patients undergoing upper endoscopic ultrasound

          3. American Society of Anesthesiology (ASA) Physical Status I-III

          4. BMI â‰¥35 kg/m2 or documented Obstructive Sleep Apnea

          5. Has provided written informed consent

        Exclusion Criteria:

          1. Inpatient status

          2. Active Congestive Heart Failure Exacerbation

          3. Untreated ischemic heart disease

          4. Acute exacerbation of respiratory disorders, including COPD and asthma

          5. Emergent procedures

          6. Pregnancy

          7. Previous enrollment in this study

          8. Inability to provide informed consent

          9. Additional medical testing planned for the same day

         10. History of allergic reaction to Propofol

         11. Tracheostomy

         12. Supra-glottic or sub-glottic tumor

         13. Gastrointestinal tract obstruction or delayed transit (including delayed gastric
             emptying, gastric bezoar, achalasia, toxic megacolon).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>john M DeWitt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martha Mendez, MSN</last_name>
    <phone>3179445392</phone>
    <phone_ext>3179445392</phone_ext>
    <email>mwmendez@iu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John M DeWitt, MD</last_name>
    <phone>317-944-0886</phone>
    <email>dodewitt@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana University Health University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha W Mendez, MSN</last_name>
      <phone>317-944-5392</phone>
      <email>mwmendez@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>John m. DeWitt, M.D.</last_name>
      <phone>317-944-0880</phone>
      <email>jodewitt@iu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John M DeWitt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John M. DeWitt, M.D.</last_name>
      <phone>317-944-0880</phone>
      <email>jodewitt@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Martha W Mendez, MSN</last_name>
      <phone>317-944-5392</phone>
      <email>mwmendez@iu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John M DeWitt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 8, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>April 19, 2020</last_update_submitted>
  <last_update_submitted_qc>April 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>John DeWitt</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

